Sean D. Reiff

Sean D. Reiff

Auto-generated profile, based on publicly available information

Sean D. Reiff

Ohio State University, Columbus, Ohio

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JWJennifer A. Woyach
Jennifer A. Woyach
DSDeborah M. Stephens
Deborah M. Stephens
IFIan W. Flinn
Ian W. Flinn
SBSeema A. Bhat
Seema A. Bhat
RSRonald E. Savage
Ronald E. Savage
JBJohn C. Byrd
John C. Byrd
Nemtabrutinib is an orally bioavailable, reversible inhibitor of Bruton tyrosine kinase (BTK) and C481S mutant BTK. We evaluated the safety, pharmacology, and antitumor activity of nemtabrutinib in relapsed/refractory hematologic malignancies. Forty-eight patients with chronic lymphocytic leukemia (CLL), B-cell non–Hodgkin lymphoma (NHL), or Waldenström macroglobulinemia (WM), relapsed/refractory after ≥2 prior therapies were enrolled in the open-label, single-arm, phase I MK-1026-001 study (NCT03162536) to receive nemtabrutinib 5 to 75 mg once daily in 28-day cycles. Dose finding progressed using a 3 + 3 dose escalation design. Primary endpoints were safety and the recommended phase II dose (RP2D). Among 47 treated patients, 29 had CLL, 17 had NHL, and 1 had WM. Grade ≥3 treatment-emergent adverse events occurred in 37 (89%), most commonly neutropenia (11; 23.4%), febrile neutropenia (7; 14.9%), and pneumonia (7; 14.9%). The RP2D was 65 mg daily. An overall response rate of 75% was observed in patients with CLL at 65 mg daily. Significance: This first-in-human phase I study demonstrates the safety and preliminary efficacy of nemtabrutinib in patients with relapsed/refractory B-cell malignancies. These data support further exploration of nemtabrutinib in larger clinical studies. This article is featured in Selected Articles from This Issue, p. 5

3 April 2023
Verified
Other
Open access
SRSean D. Reiff
Sean D. Reiff
RMRose Mantel
Rose Mantel
LSLisa L. Smith
Lisa L. Smith
JGJ.T. Greene
J.T. Greene
EMElizabeth M. Muhowski
Elizabeth M. Muhowski
JWJennifer A. Woyach
Jennifer A. Woyach

3 April 2023
Verified
Other
Open access
SRSean D. Reiff
Sean D. Reiff
RMRose Mantel
Rose Mantel
LSLisa L. Smith
Lisa L. Smith
JGJ.T. Greene
J.T. Greene
EMElizabeth M. Muhowski
Elizabeth M. Muhowski
JWJennifer A. Woyach
Jennifer A. Woyach

12 January 2024
Verified
Other
Open access
JWJennifer A. Woyach
Jennifer A. Woyach
DSDeborah M. Stephens
Deborah M. Stephens
IFIan W. Flinn
Ian W. Flinn
SBSeema A. Bhat
Seema A. Bhat
RSRonald E. Savage
Ronald E. Savage
JBJohn C. Byrd
John C. Byrd
Nemtabrutinib is an orally bioavailable, reversible inhibitor of Bruton tyrosine kinase (BTK) and C481S mutant BTK. We evaluated the safety, pharmacology, and antitumor activity of nemtabrutinib in relapsed/refractory hematologic malignancies. Forty-eight patients with chronic lymphocytic leukemia (CLL), B-cell non–Hodgkin lymphoma (NHL), or Waldenström macroglobulinemia (WM), relapsed/refractory after ≥2 prior therapies were enrolled in the open-label, single-arm, phase I MK-1026-001 study (NCT03162536) to receive nemtabrutinib 5 to 75 mg once daily in 28-day cycles. Dose finding progressed using a 3 + 3 dose escalation design. Primary endpoints were safety and the recommended phase II dose (RP2D). Among 47 treated patients, 29 had CLL, 17 had NHL, and 1 had WM. Grade ≥3 treatment-emergent adverse events occurred in 37 (89%), most commonly neutropenia (11; 23.4%), febrile neutropenia (7; 14.9%), and pneumonia (7; 14.9%). The RP2D was 65 mg daily. An overall response rate of 75% was observed in patients with CLL at 65 mg daily.Significance:This first-in-human phase I study demonstrates the safety and preliminary efficacy of nemtabrutinib in patients with relapsed/refractory B-cell malignancies. These data support further exploration of nemtabrutinib in larger clinical studies.This article is featured in Selected Articles from This Issue, p. 5

3 April 2023
Verified
Other
Open access
SRSean D. Reiff
Sean D. Reiff
RMRose Mantel
Rose Mantel
LSLisa L. Smith
Lisa L. Smith
JGJ.T. Greene
J.T. Greene
EMElizabeth M. Muhowski
Elizabeth M. Muhowski
JWJennifer A. Woyach
Jennifer A. Woyach

12 January 2024
Verified
Other
Open access
JWJennifer A. Woyach
Jennifer A. Woyach
DSDeborah M. Stephens
Deborah M. Stephens
IFIan W. Flinn
Ian W. Flinn
SBSeema A. Bhat
Seema A. Bhat
RSRonald E. Savage
Ronald E. Savage
JBJohn C. Byrd
John C. Byrd
Nemtabrutinib is an orally bioavailable, reversible inhibitor of Bruton tyrosine kinase (BTK) and C481S mutant BTK. We evaluated the safety, pharmacology, and antitumor activity of nemtabrutinib in relapsed/refractory hematologic malignancies. Forty-eight patients with chronic lymphocytic leukemia (CLL), B-cell non–Hodgkin lymphoma (NHL), or Waldenström macroglobulinemia (WM), relapsed/refractory after ≥2 prior therapies were enrolled in the open-label, single-arm, phase I MK-1026-001 study (NCT03162536) to receive nemtabrutinib 5 to 75 mg once daily in 28-day cycles. Dose finding progressed using a 3 + 3 dose escalation design. Primary endpoints were safety and the recommended phase II dose (RP2D). Among 47 treated patients, 29 had CLL, 17 had NHL, and 1 had WM. Grade ≥3 treatment-emergent adverse events occurred in 37 (89%), most commonly neutropenia (11; 23.4%), febrile neutropenia (7; 14.9%), and pneumonia (7; 14.9%). The RP2D was 65 mg daily. An overall response rate of 75% was observed in patients with CLL at 65 mg daily.Significance:This first-in-human phase I study demonstrates the safety and preliminary efficacy of nemtabrutinib in patients with relapsed/refractory B-cell malignancies. These data support further exploration of nemtabrutinib in larger clinical studies.This article is featured in Selected Articles from This Issue, p. 5